Improving response inhibition in Parkinson's disease with atomoxetine.
Bottom Line: We therefore examined the effect of the selective noradrenaline reuptake inhibitor atomoxetine on response inhibition in a stop-signal paradigm.The effects of disease and drug on behavioral performance, regional brain activity, and functional connectivity were analyzed using general linear models.Although there was no overall behavioral benefit from atomoxetine, analyses of individual differences revealed that enhanced response inhibition by atomoxetine was associated with increased RIFG activation and functional frontostriatal connectivity.
Affiliation: Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.Show MeSH
Related in: MedlinePlus
Mentions: Figure 1 presents inhibition-related activations, including the RIFG, in each group. Control subjects showed RIFG activations for SS > Go (peak coordinates in MNI space [54 18 8], t = 7.17, 1621 voxels) and for NoGo > Go (peak [48 18 −2], t = 6.00, 452 voxels; Figure 1A). The stop-related RIFG activation (SS > Go), not the NoGo-related activation (NoGo > Go), was significantly reduced in PD-placebo compared with control subjects (disease effect, peak [56 16 12], t = 3.88, 14 voxels; Figure 1A).
Affiliation: Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.